NCT02512926View on ClinicalTrials.gov

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 16, 2016

Primary Completion Date

August 28, 2021

Study Completion Date

November 7, 2023

Conditions
Relapsed Solid TumorsRefractory Solid TumorsRelapsed LeukemiaRefractory Leukemia
Interventions
DRUG

Carfilzomib

Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias

DRUG

Cyclophosphamide

DRUG

Etoposide

Trial Locations (8)

10065

Memorial Sloan-Kettering Cancer Center, New York

72202

Arkansas Children's Hospital, Little Rock

78229

University of Texas Health Science Center at San Antonio, San Antonio

85016

Phoenix Children's Hospital, Phoenix

94304

Stanford University School of Medicine and Stanford Cancer Institute, Palo Alto

02215

Dana Farber Cancer Institute, Boston

17033-0850

Penn State Hershey Children's Hospital, Hershey

T3B 6A8

Alberta Children's Hospital, Calgary

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Pediatric Oncology Experimental Therapeutics Investigators' Consortium

UNKNOWN

collaborator

Amgen

INDUSTRY

lead

Stanford University

OTHER